Literature DB >> 29019615

Haemodynamic profiles of children with end-stage heart failure.

Sharon Chen1, John C Dykes1, Doff B McElhinney1, Robert J Gajarski2, Andrew Y Shin1, Seth A Hollander1, Melanie E Everitt3, Jack F Price4, Ravi R Thiagarajan5, Steven J Kindel6, Joseph W Rossano7, Beth D Kaufman1, Lindsay J May8, Elizabeth Pruitt9, David N Rosenthal1, Christopher S Almond1.   

Abstract

AIMS: To evaluate associations between haemodynamic profiles and symptoms, end-organ function and outcome in children listed for heart transplantation. METHODS AND
RESULTS: Children <18 years listed for heart transplant between 1993 and 2013 with cardiac catheterization data [pulmonary capillary wedge pressure (PCWP), right atrial pressure (RAP), and cardiac index (CI)] in the Pediatric Heart Transplant Study database were included. Outcomes were New York Heart Association (NYHA)/Ross classification, renal and hepatic dysfunction, and death or clinical deterioration while on waitlist. Among 1059 children analysed, median age was 6.9 years and 46% had dilated cardiomyopathy. Overall, 58% had congestion (PCWP >15 mmHg), 28% had severe congestion (PCWP >22 mmHg), and 22% low cardiac output (CI < 2.2 L/min/m2). Twenty-one per cent met the primary outcome of death (9%) or clinical deterioration (12%). In multivariable analysis, worse NYHA/Ross classification was associated with increased PCWP [odds ratio (OR) 1.03, 95% confidence interval (95% CI) 1.01-1.07, P = 0.01], renal dysfunction with increased RAP (OR 1.04, 95% CI 1.01-1.08, P = 0.007), and hepatic dysfunction with both increased PCWP (OR 1.03, 95% CI 1.01-1.06, P < 0.001) and increased RAP (OR 1.09, 95% CI 1.06-1.12, P < 0.001). There were no associations with low output. Death or clinical deterioration was associated with severe congestion (OR 1.6, 95% CI 1.2-2.2, P = 0.002), but not with CI alone. However, children with both low output and severe congestion were at highest risk (OR 1.9, 95% CI 1.1-3.5, P = 0.03).
CONCLUSION: Congestion is more common than low cardiac output in children with end-stage heart failure and correlates with NYHA/Ross classification and end-organ dysfunction. Children with both congestion and low output have the highest risk of death or clinical deterioration. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Haemodynamics; Paediatric heart failure

Mesh:

Year:  2017        PMID: 29019615     DOI: 10.1093/eurheartj/ehx456

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

Review 1.  Drug Treatment of Heart Failure in Children: Gaps and Opportunities.

Authors:  Molly Weisert; Jennifer A Su; Jondavid Menteer; Robert E Shaddy; Paul F Kantor
Journal:  Paediatr Drugs       Date:  2022-01-27       Impact factor: 3.022

2.  Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But….

Authors:  Dietmar Schranz
Journal:  Paediatr Drugs       Date:  2022-08-06       Impact factor: 3.930

3.  Epidemiology and Outcomes of Acute Decompensated Heart Failure in Children.

Authors:  Javier J Lasa; Michael Gaies; Lauren Bush; Wenying Zhang; Mousumi Banerjee; Jeffrey A Alten; Ryan J Butts; Antonio G Cabrera; Paul A Checchia; Justin Elhoff; Angela Lorts; Joseph W Rossano; Kurt Schumacher; Lara S Shekerdemian; Jack F Price
Journal:  Circ Heart Fail       Date:  2020-04-17       Impact factor: 8.790

Review 4.  Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials.

Authors:  Bibhuti B Das; William B Moskowitz; Javed Butler
Journal:  Children (Basel)       Date:  2021-04-22

Review 5.  Current State of Pediatric Heart Failure.

Authors:  Bibhuti B Das
Journal:  Children (Basel)       Date:  2018-06-28

Review 6.  Invasive Haemodynamic Assessment Before and After Left Ventricular Assist Device Implantation: A Guide to Current Practice.

Authors:  Jesus Gonzalez; Paul Callan
Journal:  Interv Cardiol       Date:  2021-12-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.